We are occasionally asked about the success rate of different antibody platforms for drug discovery. There are a variety of technologies available for therapeutic antibody discovery: conventional mice where the Abs are humanized, human Ab transgenic rodents, human Ab synthetic phage and yeast libraries, and others.
However, the majority (~85%) of approved antibody therapeutics have been obtained from immunized conventional or human Ab transgenic rodents versus synthetic libraries.
This observation is confirmed in a recent white paper by Andrew Burrows, The Future of Monoclonal Antibodies (KNECT 365 Life Sciences). The article lists 10 Abs that have been newly FDA approved in Q1-Q3, 2018, and 18 therapeutic Abs approaching BLA or under FDA review. Of the 10 newly approved Abs, 7 were obtained by humanization of conventional mouse Abs, 2 were from human Ab-producing transgenic mice and one from phage display. Of the 18 therapeutic antibodies approaching BLA or under FDA review, 11 are humanized, 4 from transgenic mice, 1 is a mouse - human chimera, 1 is a Camelid bivalent VHH, and 1 is an Ab from Ribosome Display. Thus, 25 out of 28 Abs (89%) of newly approved or pending approval therapeutic Abs were derived from immunized rodents. At Antibody Solutions, we focus on Abs generated by conventional or human Ab transgenic rodents since they have a proven track record for generating the majority of therapeutic antibodies.